Vir Biotechnology (VIR) Cash from Investing Activities (2018 - 2026)

Vir Biotechnology (VIR) has 9 years of Cash from Investing Activities data on file, last reported at $11.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 90.67% year-over-year to $11.8 million; the trailing twelve-month figure through Mar 2026 stood at $195.4 million (down 67.31% YoY), and the FY2025 full-year result was $310.4 million, down 37.85% from the prior year.
• Cash from Investing Activities fell to $11.8 million in Q1 2026, from $86.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $230.3 million in Q2 2023 to a low of -$662.6 million in Q3 2022.
• A 5-year average of -$12.2 million and a median of $40.4 million in 2025 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities sank 997.12% in 2022 and jumped 346.23% in 2025, its largest moves.
• Tracing VIR's Cash from Investing Activities over 5 years: stood at -$153.1 million in 2022, then surged by 31.56% to -$104.8 million in 2023, then soared by 234.28% to $140.7 million in 2024, then slumped by 38.43% to $86.7 million in 2025, then sank by 86.34% to $11.8 million in 2026.
• Business Quant data shows VIR's Cash from Investing Activities at $11.8 million in Q1 2026, $86.7 million in Q4 2025, and $40.4 million in Q3 2025.